Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Update

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) was the recipient of a significant drop in short interest in the month of February. As of February 15th, there was short interest totalling 61,900 shares, a drop of 55.3% from the January 31st total of 138,500 shares. Approximately 3.4% of the shares of the company are short sold. Based on an average daily volume of 4,630,000 shares, the days-to-cover ratio is currently 0.0 days.

Cyclerion Therapeutics Trading Down 5.3 %

Shares of NASDAQ:CYCN opened at $2.67 on Friday. The company has a 50-day moving average price of $3.19 and a two-hundred day moving average price of $2.93. Cyclerion Therapeutics has a twelve month low of $1.27 and a twelve month high of $9.47.

Hedge Funds Weigh In On Cyclerion Therapeutics

A hedge fund recently bought a new stake in Cyclerion Therapeutics stock. Renaissance Technologies LLC acquired a new stake in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 10,611 shares of the company’s stock, valued at approximately $34,000. Renaissance Technologies LLC owned 0.39% of Cyclerion Therapeutics at the end of the most recent quarter. 75.62% of the stock is currently owned by hedge funds and other institutional investors.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.